Literature DB >> 16789929

Therapeutic angiogenesis by intramuscular injection of fibrin particles into ischaemic hindlimbs.

Chun-Ling Fan1, Ping-Jin Gao, Yuan-Jun Gu, Xiao-Feng Tang, Jian-Jun Liu, Jian Wei, Kazutomo Inoue, Ding-Liang Zhu.   

Abstract

1. Fibrin gel has been used as a carrier of angiogenic molecules to promote neovascularization in animal models of limb ischaemia. However, little is known about the effects of fibrin itself under such pathological conditions. Accordingly, the present study tested the efficacy of fibrin in a rabbit model of acute hindlimb ischaemia. 2. Unilateral ischaemia was induced by resection of the left femoral artery. Seven days after surgery, fibrin particles (FP), which were free of fibrinogen, thrombin and vascular endothelial growth factor, were injected directly into the ischaemic thigh muscles. Twenty-four rabbits were divided into four groups, namely a control group receiving phosphate-buffered saline and three FP-treated groups receiving 5, 10 or 20 mg FP. 3. Collateral vessel development and limb perfusion were assessed by angiography, measuring the calf blood pressure ratio (BPR), thermographic scanning and the histological determination of capillary density. 4. At day 35 post-surgery, the treatment with 5 mg FP produced an augmentation of collateral vessel development (P < 0.01), increased numbers of capillaries (P < 0.05) and improved perfusion manifested by a higher blood flow (P < 0.01) and calf BPR (P < 0.05) compared with controls. Treatment with 10 and 20 mg FP had similar effects to those observed with 5 mg FP. 5. The present study reveals that FP promotes angiogenesis in a rabbit model of hindlimb ischaemia, thus providing a feasible approach to therapeutic angiogenesis in ischaemic diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16789929     DOI: 10.1111/j.1440-1681.2006.04416.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  9 in total

1.  Fibrin acts as biomimetic niche inducing both differentiation and stem cell marker expression of early human endothelial progenitor cells.

Authors:  M C Barsotti; A Magera; C Armani; F Chiellini; F Felice; D Dinucci; A M Piras; A Minnocci; R Solaro; G Soldani; A Balbarini; R Di Stefano
Journal:  Cell Prolif       Date:  2011-02       Impact factor: 6.831

2.  Fabrication and characterization of injectable hydrogels derived from decellularized skeletal and cardiac muscle.

Authors:  J L Ungerleider; T D Johnson; N Rao; K L Christman
Journal:  Methods       Date:  2015-04-02       Impact factor: 3.608

Review 3.  Concise review: injectable biomaterials for the treatment of myocardial infarction and peripheral artery disease: translational challenges and progress.

Authors:  Jessica L Ungerleider; Karen L Christman
Journal:  Stem Cells Transl Med       Date:  2014-07-10       Impact factor: 6.940

4.  A combined synthetic-fibrin scaffold supports growth and cardiomyogenic commitment of human placental derived stem cells.

Authors:  Antonella Lisi; Enrica Briganti; Mario Ledda; Paola Losi; Settimio Grimaldi; Rodolfo Marchese; Giorgio Soldani
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

5.  Hypoxic preconditioning-induced autophagy enhances survival of engrafted endothelial progenitor cells in ischaemic limb.

Authors:  Pei Zhou; Yu-Zhen Tan; Hai-Jie Wang; Guo-Dong Wang
Journal:  J Cell Mol Med       Date:  2017-04-04       Impact factor: 5.310

Review 6.  Therapeutic Biomaterial Approaches to Alleviate Chronic Limb Threatening Ischemia.

Authors:  Grazia Marsico; Sergio Martin-Saldaña; Abhay Pandit
Journal:  Adv Sci (Weinh)       Date:  2021-02-08       Impact factor: 16.806

7.  Protease-activated receptor (PAR)2, but not PAR1, is involved in collateral formation and anti-inflammatory monocyte polarization in a mouse hind limb ischemia model.

Authors:  Lisa G van den Hengel; Alwine A Hellingman; Anne Yael Nossent; Annemarie M van Oeveren-Rietdijk; Margreet R de Vries; C Arnold Spek; Anton Jan van Zonneveld; Pieter H Reitsma; Jaap F Hamming; Hetty C de Boer; Henri H Versteeg; Paul H A Quax
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

8.  Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic sclerosis.

Authors:  Shadab Allipour Birgani; Marion Mailänder; Ines Wasle; Hermann Dietrich; Johann Gruber; Oliver Distler; Roswitha Sgonc
Journal:  Ann Rheum Dis       Date:  2015-09-11       Impact factor: 19.103

9.  Designing Acellular Injectable Biomaterial Therapeutics for Treating Myocardial Infarction and Peripheral Artery Disease.

Authors:  Melissa J Hernandez; Karen L Christman
Journal:  JACC Basic Transl Sci       Date:  2017-04-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.